Trade Cumberland - CPIX CFD
Add to favourite- Summary
- Historical Data
| Spread | 0.1066 | ||||||||
|
Long position overnight fee
Long position overnight funding adjustment
Go to platform | -0.023679% | ||||||||
|
Short position overnight fee
Short position overnight funding adjustment
Go to platform | 0.001457% | ||||||||
| Overnight fee time | 21:00 (UTC) | ||||||||
| Min traded quantity | 1 | ||||||||
| Currency | USD | ||||||||
| Margin | 5.00% | ||||||||
| Stock exchange | United States of America | ||||||||
| Commission on trade | 0% |
| Prev. Close | 4.8267 |
| Open | 4.7067 |
| 1-Year Change | 212.57% |
| Day's Range | 4.7067 - 4.8767 |
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
| Date | Close | Change | Change (%) | Open | High | Low |
|---|---|---|---|---|---|---|
| Apr 30, 2025 | 4.8267 | 0.1100 | 2.33% | 4.7167 | 4.8267 | 4.6467 |
| Apr 29, 2025 | 4.8467 | 0.1800 | 3.86% | 4.6667 | 4.9267 | 4.6567 |
| Apr 28, 2025 | 4.6867 | -0.3000 | -6.02% | 4.9867 | 5.0467 | 4.5967 |
| Apr 25, 2025 | 4.9167 | 0.0500 | 1.03% | 4.8667 | 4.9867 | 4.8567 |
| Apr 24, 2025 | 4.7567 | -0.3700 | -7.22% | 5.1267 | 5.1267 | 4.7167 |
| Apr 23, 2025 | 4.9467 | 0.0000 | 0.00% | 4.9467 | 5.2367 | 4.6767 |
| Apr 22, 2025 | 4.9667 | 0.5200 | 11.69% | 4.4467 | 5.0667 | 4.4467 |
| Apr 21, 2025 | 4.4667 | -0.1900 | -4.08% | 4.6567 | 4.8067 | 4.3867 |
| Apr 17, 2025 | 4.6767 | 0.1500 | 3.31% | 4.5267 | 4.7567 | 4.3367 |
| Apr 16, 2025 | 4.4667 | 0.4300 | 10.65% | 4.0367 | 4.4967 | 3.9967 |
| Apr 15, 2025 | 4.0967 | -0.1000 | -2.38% | 4.1967 | 4.2267 | 4.0267 |
| Apr 14, 2025 | 4.1067 | 0.3000 | 7.88% | 3.8067 | 4.1467 | 3.8067 |
| Apr 11, 2025 | 4.0767 | 0.2500 | 6.53% | 3.8267 | 4.0867 | 3.7767 |
| Apr 10, 2025 | 3.9467 | -0.2100 | -5.05% | 4.1567 | 4.2167 | 3.7567 |
| Apr 9, 2025 | 4.0167 | 0.0600 | 1.52% | 3.9567 | 4.1667 | 3.7867 |
| Apr 8, 2025 | 3.9067 | -0.2200 | -5.33% | 4.1267 | 4.1367 | 3.7967 |
| Apr 7, 2025 | 4.1067 | 0.0200 | 0.49% | 4.0867 | 4.2367 | 4.0167 |
| Apr 4, 2025 | 4.1267 | -0.0400 | -0.96% | 4.1667 | 4.1967 | 4.0967 |
| Apr 3, 2025 | 4.2967 | 0.1000 | 2.38% | 4.1967 | 4.3567 | 4.0467 |
| Apr 2, 2025 | 4.2667 | 0.0200 | 0.47% | 4.2467 | 4.3767 | 4.2167 |
Trading calculator
Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).
- 1:1
- 2:1
- 3:1
- 5:1
- 10:1
- 20:1
- 20
- 100
- 500
- 1000
- 10000
Cumberland Company profile
About Cumberland Pharmaceuticals, Inc.
Cumberland Pharmaceuticals Inc. is a specialty pharmaceutical company focused on the acquisition, development and commercialization of prescription products. The Company's product portfolio includes Acetadote (acetylcysteine) Injection, for the treatment of acetaminophen poisoning; Caldolor (ibuprofen) Injection, for the treatment of pain and fever; Kristalose (lactulose) for Oral Solution, a prescription laxative, for the treatment of chronic and acute constipation; Omeclamox Pak, (omeprazole, clarithromycin, amoxicillin) for the treatment of Helicobacter pylori (H. pylori) infection and related duodenal ulcer disease; Vaprisol (conivaptan) Injection, to raise serum sodium levels in hospitalized patients with euvolemic and hypervolemic hyponatremia; Vibativ (telavancin) Injection, for the treatment of certain serious bacterial infections, including hospital-acquired and ventilator-associated bacterial pneumonia, as well as complicated skin and skin structure infections; and RediTrex.
Financial summary
BRIEF: For the fiscal year ended 31 December 2021, Cumberland Pharmaceuticals, Inc. revenues decreased 4% to $36M. Net loss before extraordinary items decreased 16% to $5.5M. Revenues reflect Acetadote segment decrease of 55% to $851K, RediTrex segment decrease of 94% to $55K. Lower net loss reflects Interest expense decrease of 63% to $98K (expense), Research and Development decrease of 2% to $5.7M (expense).
Equity composition
Common stock no par, 03/11, 100M auth., 20,432,034 issd. Insider owns approx. 37.85% .IPO:8/11/2009, 5M shares @ $17 per share by UBS Securities LLC, Jefferies & Company, Inc., Wells Fargo Securities, LLC & MorganJoseph & Co. Inc. 6/07,Stock Split 2:1.
| Industry: | Generic Pharmaceuticals |
2525 W End Ave Ste 950
NASHVILLE
TENNESSEE 37203-1608
US
News
GME shares price forecast: Third-party price target
Read our GameStop (GME) share price forecast for 2025 and beyond, with insights from third-party analysts and market experts
11:40, 28 April 2025
ECB interest-rate forecasts – Projections for the next five years
The European Central Bank (ECB) plays a pivotal role in the economic stability of the eurozone, meaning ECB interest-rate forecasts are key to understanding how financial and economic scenarios might evolve.
14:37, 10 April 2025
BlackRock shareholders: Who owns the most BLK stock?
BlackRock is the leading asset manager in the world – but who are its biggest shareholders? Read on to find out.
13:46, 9 April 2025
Bitcoin price predictions 2025–2050: third-party price target
We examine bitcoin price predictions for 2025 and beyond, with insights from third-party analysts and market experts.
10:28, 9 April 2025
Tesla (TSLA) stock forecast 2025 and beyond: third-party Tesla price target
Where will Tesla’s stock be in five years? Can the EV company keep its crown?
08:19, 9 April 2025
JasmyCoin price predictions 2025-2030: Third-party price target
How might JASMY behave in the future?
16:13, 8 April 2025
Australian interest-rate projections: where will rates be in 5 years?
As one of the most closely watched economic indicators, Australian interest-rate projections offer valuable insight into the future of the country’s economy.
21:37, 7 April 2025People also watch
Still looking for a broker you can trust?
Join the 720,000+ traders worldwide that chose to trade with Capital.com